CRESCENT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
CRESCENT BIOPHARMA, INC. (CBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $140.68 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2025-05-14
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-03-31 was $140.68K, a 53.91% decline year-over-year.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-03-31 was $305.22K, a 68.60% increase year-over-year.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-03-31 was $181.03K, a 1597.12% increase year-over-year.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-03-31 was $10.67K, a 383.76% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month |
|---|---|
| 2025-03-31 | $140.68K 10-Q · filed 2025-05-14 |
| 2024-03-31 | $305.22K 10-Q · filed 2025-05-14 |
| 2023-03-31 | $181.03K 10-Q · filed 2024-05-09 |
| 2022-03-31 | $10.67K 10-Q · filed 2023-05-03 |
| 2021-03-31 | $2.21K 10-Q · filed 2022-04-28 |
| 2014-03-31 | $17.82K 10-Q · filed 2014-05-09 |
| 2013-03-31 | $77.54K 10-Q · filed 2014-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |